Global Oncology Biosimilars Market Expected to Touch a Value of US$17,478.2 mn by 2025
New research report offers a comprehensive analysis of the “Oncology Biosimilars Market – Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 – 2025” The main objective of this report is to deliver insightful information and clear-cut facts pertaining to the growth trajectories of the market.
Request to view Sample Report @ https://www.mrrse.com/sample/3535
Global Oncology Biosimilars Market: Snapshot
The global oncology biosimilars market is predicted to benefit immensely with the rising demand for affordable therapies for cancer. This is because cancer is presently the costliest health affair in terms of both diagnosis and treatment. Pharmaceutical companies worldwide are hard-focused on developing biosimilars and generic medicines to combat cancer at all stages and also for the treatment of the disease.
Oncology biosimilars are similar versions of oncology biologics that are manufactured by different companies and have been officially approved for cancer treatment. Biosimilars are cost-effective molecules with the same efficacy and potency as the original reference biologic. The relatively easy manufacturing of biosimilars and the license to manufacture biosimilars after the expiration of original reference biologic is acting in favor of the global oncology biosimilars market.
On the down side, complex infrastructure needed for the development of biosimilars and lengthy process for the approval of biosimilars is providing headwinds to the market’s growth.
A report by Transparency Market Research estimates the global oncology biosimilars market to expand at an outstanding 27.5% CAGR between 2017 and 2025, for the market to become worth US$17,478.2 mn by the end of 2025 considerably up from its evaluated worth ofUS$2,100 mn in 2016.
G-CSF Drug Class Segment Gains from Patent Expiration of Original Biologics
The report studies the global oncology biosimilars market based on a few parameters. The segments into which the oncology biosimilars market is divided depending upon drug class are G-CSF, monoclonal antibody, and hematopoietic agents. In 2016, the G-CSF segment dominated the market in terms of revenue, and the segment is expected to lead until the end of 2025. The G-CSF drug class segment is leading mainly because of a robust pipeline of oncology biosimilars of key players in the market. Moreover, patent expirations of reference biologics is contributing to the growth of G-CSF drug class segment.
Browse Full Report with TOC @ https://www.mrrse.com/oncology-biosimilars-market
Based on disease indication the market has been segmented into breast cancer, blood cancer, colorectal cancer, non-small cell lung cancer, neutropenia, and others. Blood cancer segment has been further sub-segmented into leukemia and non-Hodgkin’s lymphoma. Of them, neutropenia led the market in 2016. Going forward too, neutropenia segment is anticipated to remain dominant over the forecast period. The strong growth of this segment is attributed to patent expiration of blockbuster oncology biologics and efforts from several governments to make affordable medicines accessible to patients. Also, the growth of neutropenia segment is driven by approvals received by numerous manufacturers in Europe to manufacture filgrastim and Peg-Filgrastim. The blood cancer segment is predicted to display a robust CAGR over the forecast period owing to a large number of pipeline of biosimilars, and the rising adoption of biosimilars among physicians and patients.
On the basis of distribution channel, the segments into which the global oncology biosimilars market has been segmented in this report are hospital pharmacy, retail pharmacy, and online pharmacy. Vis-à-vis revenue, hospital pharmacy led the market in 2016, and the segment is expected to remain dominant over the forecast period.
Efforts of Players to Enter into Strategic Alliances Benefit Asia Pacific Market
Geography-wise, North America, Europe, Asia Pacific, and Rest of the World are key segments that divide the global oncology biosimilars market. Asia Pacific held a significant share of the oncology biosimilars market in 2016. This is mainly because of low cost of biosimilars as compared to original reference biologics and availability of cost effective and safe cancer medications via retail stores in this region. In addition, focus of leading players in the region to enter to strategic alliances for expanding outreach is also benefitting the Asia Pacific oncology biosimilars market.
Leading companies in the global oncology biosimilars market that are profiled in this report are Celltrion Inc., Biocon, Dr. Reddy’s Laboratories Ltd., STADA Arzneimittel AG, Intas Pharmaceuticals Ltd., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Apotex Inc., and BIOCAD.
Enquire about this Report @ https://www.mrrse.com/enquiry/3535
Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207
United States Telephone: +1-518-730-0559
Read More Industry News At: https://www.industrynewsanalysis.com/